Trial Profile
A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2022
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Capecitabine; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress
- 18 Feb 2020 Planned End Date changed from 1 Jun 2020 to 30 Nov 2020.
- 14 Jan 2018 Planned number of patients changed from 40 to 48.